Melissa Devsam Email & Phone Number

Sydney, New South Wales, Australia

Macquarie Park, New South Wales, Australia

April 2022 - Dec 2022 (Maternity Leave)Feb 2021 - Dec 2022General Medicine Leadership Team Member, responsible for organisational leadership decisions that impact the general medicine business unit.Sept 2021 - April 2022Commercial Lead for Lagevrio (Molnupiravir) COVID-19 antiviral treatment. Managing marketers and hospital sales representatives as we prepare to accelerate the launch for a much needed treatment to help curb the pandemic.Feb 2020 - Aug 2021National Hospital Sales Manager of Infectious Diseases Sales Team and Marketing responsibility of P1 product Zerbaxa (gram-negative antibiotic for hospital acquired infections) and commercial leader of HIV portfolio and pipeline.My sales team is a high performing, highly knowledgeable and talented team working on complex infectious disease treatments in the private market in tertiary public hospitals in the areas of CMV, c. Diff and MDR infections. The team go above and beyond their sales role with opportunities to build experience in areas like policy engagement and digital marketing.I’m proud to be their manager, coach and leader as we navigate these challenging and continually changing environment.

Sydney, Australia

Macquarie Park, New South Wales, Australia

Infectious Disease Portfolio Lead for Antibiotics, with a focus on Zerbaxa, Dificid, Zinplava and Cubicin for the Australian market.Current focus is on:(1) Improving Sales Force Effectiveness(2) Develop new medical education platform & diagnostic access program to enable earlier diagnosis for severely ill patients(3) Increasing Market Access more immediately in a private market setting and shaping long-term access for new antibiotics(4) Preparing launch of a new indicationAntimicrobial resistance is an important public health issue globally & the solution is complex. MSD is one of the few innovative companies committed to R&D in infectious diseases and tackling the issues to help ensure we have antibiotics in the future. Check out the videos below as an example of what my colleagues in UK, US and Canada are facing - it is a very similar situation in Australia.

Sydney, Australia

Point of Care DivisionJoined a mature business to launch the new iSTAT Alinity point of care diagnostic device in Australia & New Zealand and led the pre-launch activities for the game-changing High Sense Troponin Assay for iSTAT.Gaining experience in capital equipment in the medical device arena & an understanding of the regulatory & market access environment for diagnostic products.The iSTAT enables point of care diagnostics of Blood Gases, Electrolytes, Cardiac Biomarkers, Endocrine Biomarkers and Coagulation.https://www.pointofcare.abbott/int/en/offerings/istat/istat-test-cartridges The new high sense Troponin assay has significant value in preventing hospital admission of 40% of Chest Pain patients as it enables ambulances to evaluate chest pain patients in the field, which can save governments millions. I built stakeholder maps, established an advisory committee, set up a cross-Tasman / cross-functional working group and led the design of the 1st advisory board globally for the product, which can be leveraged for the APAC region.In addition, as part of the Alinity launch - in order to better evaluate the potential for hospitals to upgrade from the old iSTAT to the new Alinity (the difference is like the Nokia verses the iPhone) - I had to set up foundations for commercial effectiveness which the division had not established. This involved procurement of data and a software interface that enables the sales force to quickly assess hospitals that are high potential. This was done by modelling our archetypes of successful hospitals and identifying & classifying hospitals based on these archetypes. Understanding the usage of the cartridge menu by department. I had completed this project and rolled out to the senior management team in April 2018.

North Ryde, New South Wales, Australia

(Feb 2017 - July 2017) Diabetes TeamJoined MSD's 2017 'must win' franchise in primary care, leading their Hospital Team Strategy and Pre-Launch activities for their pipeline diabetes products. Continued to drive double digit growth in a highly competitive market place, out performing plan YTD for 2017.(2015 - Feb 2017) Cardiovascular TeamJoined MSD's largest revenue generating franchise at the Launch of AtoZet FDC. Contributed to expanding the sales force promotion by rolling-out the national training program for the PO Team. Lead the GP Strategy for 2016 across 4 national sales teams. Contributed to generating field force engagement & execution of strategy, gaining double digit growth on top of an extremely successful prior year. Lead the development of the 2017 Brand Plan and Operational Plan. Won Winners Circle 2016 for my performance in the Primary Care Business (aka. Marketer of the Year Award 2016).Additional AchievementsAccepted & participated in the Aspiring Sales Manager Program

Sydney Area, Australia

Marketing responsibility of Xiaflex and Veletri for the Australian Market as well as other pipeline product support. Diseases involved are Dupuytren's Contracture (DC) in Hand Surgery and severe Pulmonary Arterial Hypertension in Cardiology & Respiratory. Successfully Launched Veletri on 1st August 2014 into the Australian Market, achieved 50% marketshare within 4 months in a niche orphan disease market. Designed Launch Brand Assets, involved in the development of the marketing strategic plan and pre-launch customer engagement activities.Project Team Leader of Xiaflex cross-functional team during the Launch year in 2014. Designed Launch Brand Assets. Involved in the development of the strategic brand plan for 2015. Pre-marketing activities for broadening indication for the brand. Other experience includes: CRM optimisation, sales effectiveness, public speaking, conference sponsorship, video development, website design & implementation, market research input, sales forecasting and project management. HR representative for "People of Possibility" and involved in internal launch excitement campaign.

Sydney

Pulmonary arterial hypertension product portfolio key account manager for New South Wales. Specialties include: cardiology, respiratory, rheumatologists and immunologists.Product: Tracleer

Sydney Area, Australia

Managed New South Wales & South Australia for the plasma product portfolio for CSL Biotherapies Plasma Division. Key specialties include: Trauma, ED, ICU, Anaesthetics, Haematology, Neurology, Immunology and Cardiothoracic Surgery. Partnered with Australian Red Cross Blood Service to deliver on-going blood management education to hospital systems.Products: Prothrombinex-VF, Intragam-P, Albumex, RiaSTAP (Fibrinogen Concentrate), Evogam, MonoFix-VF, BiostateDiseases: Autoimmune spectrum of diseases, CIDP, Guillain-Barre Syndrome, Acute Massive Bleeding, Haemophilia spectrum of diseases, fluid resuscitation & hypoalbuminemia

Sydney

Specialties were: cardiology, respiratory, geriatrics, endocrinology, immunology and emergency departments.Products: Bicor & Diabex-XR & EpipenDiseases: Heart Failure & Diabetes & Anaphalaxis

Adelaide Area, Australia

Experience in managing a labs inventory.Designing diagnostic experiments.Chromotography, HPLC, electrophoresis, PCR, laminar flow work, quality assurance and operational safety experience.Cell apoptosis work (Cancer).Fungal pathogen work (Infectious disease).

Master Of Business Administration (Mba), Business, Management, Marketing, And Related Support Services

Completed the Grad. Dip in Management component of the MBA Executive course. Completed the Strategic Management Year in 2014. Subjects.

Bachelor Of Biotechnology (Hons), Medical

Activities and Societies: FUBA (Flinders Biotechnology Association) Tresurer (2004)Awarded 1st Class Honours for my research.

High School Certificate, Sace

Activities and Societies: Australian Young Achiever (2000), ABW Simulation Program